real-time news and commentary for investors
Tuesday, Nov 27
2012, 10:36 AM
IntelliPharmaCeutics (IPCI -4.3%) slips despite reporting successful results of its initial...
IntelliPharmaCeutics (IPCI -4.3%) slips despite reporting successful results of its initial Phase I clinical trial of a controlled-release form of pregabalin, for the treatment of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury and fibromyalgia. The results of the trial showed the drug was comparable to Pfizer's (PFE -0.6%) Lyrica, and the IPCI now plans to initiate additional Phase I trials in 2013.